Clinical and Radiographic Evaluation of Buckley's Formocresol, Aloe Vera, and EndoSequence: As Pulpotomy Medicaments in Primary Molars.

Q3 Dentistry
Sakshi Sunil Jajoo, Shweta Chaudhary, Preetam Shah, Laxmi Lakade, Rucha Davalbhakta, Smita Patil
{"title":"Clinical and Radiographic Evaluation of Buckley's Formocresol, <i>Aloe Vera</i>, and EndoSequence: As Pulpotomy Medicaments in Primary Molars.","authors":"Sakshi Sunil Jajoo, Shweta Chaudhary, Preetam Shah, Laxmi Lakade, Rucha Davalbhakta, Smita Patil","doi":"10.5005/jp-journals-10005-3186","DOIUrl":null,"url":null,"abstract":"<p><strong>Aim: </strong>The aim of this <i>in vivo</i> study is to compare the clinical and radiographic success of Buckley's Formocresol (FC), <i>Aloe vera</i>, and EndoSequence as pulpotomy medicaments in primary molars.</p><p><strong>Materials and methods: </strong>A total of 39 vital primary molars were selected and assigned to three groups: Group I-Buckley's Formocresol, Group II-<i>Aloe vera</i>, Group III-EndoSequence. The clinical and radiographic success was evaluated using Zurn and Seale criteria. The data were statistically analyzed using the Chi-square test.</p><p><strong>Results: </strong>After 3 months, the overall success rate was 92.3% in the Buckley's Formocresol group and 100% in the <i>Aloe vera</i> and EndoSequence groups. After 6 months, the overall success rate was 84.6% in the Buckley's Formocresol group, 92.3% in the <i>Aloe vera</i> group, and 100% in the EndoSequence group. There was a nonsignificant difference in the overall success between the three groups after 3 and 6 months.</p><p><strong>Conclusion: </strong>The clinical and radiographic success rates of Buckley's Formocresol, <i>Aloe vera</i>, and EndoSequence as pulpotomy medicaments in primary molars showed similar efficacy after 6 months of evaluation, although the results were not statistically significant. This states that in spite of Buckley's Formocresol being a gold standard medicament used for pulpotomy procedures, <i>Aloe vera</i>, a herbal medicament, and a newer medicament, EndoSequence, can be used as clinically effective pulpotomy medicaments with fewer limitations compared to Buckley's Formocresol.</p><p><strong>How to cite this article: </strong>Jajoo SS, Chaudhary S, Shah P, <i>et al.</i> Clinical and Radiographic Evaluation of Buckley's Formocresol, <i>Aloe Vera,</i> and EndoSequence: As Pulpotomy Medicaments in Primary Molars. Int J Clin Pediatr Dent 2025;18(7):843-847.</p>","PeriodicalId":36045,"journal":{"name":"International Journal of Clinical Pediatric Dentistry","volume":"18 7","pages":"843-847"},"PeriodicalIF":0.0000,"publicationDate":"2025-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12486554/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"International Journal of Clinical Pediatric Dentistry","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.5005/jp-journals-10005-3186","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/8/20 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"Dentistry","Score":null,"Total":0}
引用次数: 0

Abstract

Aim: The aim of this in vivo study is to compare the clinical and radiographic success of Buckley's Formocresol (FC), Aloe vera, and EndoSequence as pulpotomy medicaments in primary molars.

Materials and methods: A total of 39 vital primary molars were selected and assigned to three groups: Group I-Buckley's Formocresol, Group II-Aloe vera, Group III-EndoSequence. The clinical and radiographic success was evaluated using Zurn and Seale criteria. The data were statistically analyzed using the Chi-square test.

Results: After 3 months, the overall success rate was 92.3% in the Buckley's Formocresol group and 100% in the Aloe vera and EndoSequence groups. After 6 months, the overall success rate was 84.6% in the Buckley's Formocresol group, 92.3% in the Aloe vera group, and 100% in the EndoSequence group. There was a nonsignificant difference in the overall success between the three groups after 3 and 6 months.

Conclusion: The clinical and radiographic success rates of Buckley's Formocresol, Aloe vera, and EndoSequence as pulpotomy medicaments in primary molars showed similar efficacy after 6 months of evaluation, although the results were not statistically significant. This states that in spite of Buckley's Formocresol being a gold standard medicament used for pulpotomy procedures, Aloe vera, a herbal medicament, and a newer medicament, EndoSequence, can be used as clinically effective pulpotomy medicaments with fewer limitations compared to Buckley's Formocresol.

How to cite this article: Jajoo SS, Chaudhary S, Shah P, et al. Clinical and Radiographic Evaluation of Buckley's Formocresol, Aloe Vera, and EndoSequence: As Pulpotomy Medicaments in Primary Molars. Int J Clin Pediatr Dent 2025;18(7):843-847.

Abstract Image

Abstract Image

Abstract Image

巴克利福摩甲酚、芦荟和内窥镜:作为乳牙髓切开术药物的临床和影像学评价。
目的:本体内研究的目的是比较巴克利福摩甲酚(FC)、芦荟和EndoSequence作为初级磨牙髓切开术药物的临床和影像学成功。材料和方法:选择39颗生牙,分为3组:buckley 's Formocresol组,芦荟组,endosequence组。使用Zurn和Seale标准评估临床和影像学成功。数据采用卡方检验进行统计学分析。结果:3个月后,巴克利福摩甲酚组总成功率为92.3%,芦荟和EndoSequence组总成功率为100%。6个月后,巴克利福摩甲酚组的总成功率为84.6%,芦荟组为92.3%,EndoSequence组为100%。3个月和6个月后,三组之间的总体成功率差异不显著。结论:Buckley’s Formocresol、芦荟、EndoSequence三种药物作为一磨牙切髓药物,经过6个月的评估,临床和影像学成功率相似,但结果无统计学意义。这表明,尽管巴克利的福尔摩甲酚是用于髓切手术的金标准药物,芦荟,一种草药药物和一种新的药物,EndoSequence,可以作为临床有效的髓切药物,与巴克利的福尔摩甲酚相比,限制更少。如何引用本文:Jajoo SS, Chaudhary S, Shah P,等。巴克利福摩甲酚、芦荟和内窥镜:作为乳牙髓切开术药物的临床和影像学评价。中华临床儿科杂志,2015;18(7):843-847。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
1.20
自引率
0.00%
发文量
135
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信